What public health strategy will Indonesia adopt with the Sinovac vaccine?

Question

Accepted Answer

Indonesia Approves Sinovac Vaccine for Emergency Use

Indonesia's food and drug agency has granted emergency use approval for the Sinovac Biotech Covid-19 vaccine, marking the first country outside China to provide regulatory authorization for this particular vaccine. Interim results from late-stage human trials conducted in Indonesia indicated an efficacy rate of 65.3 per cent for the vaccine.
Regulatory Approval Granted

The Indonesian food and drug agency, known as BPOM, officially provided emergency use authorization for the Sinovac Covid-19 vaccine. This decision positions Indonesia as the first nation outside of China to grant such regulatory clearance for the vaccine developed by the Chinese company.
Vaccine Efficacy Data

During the announcement of the approval, Penny K. Lukito, the head of BPOM, shared interim findings from the late-stage human testing conducted within Indonesia. These results demonstrated that the Sinovac vaccine achieved an efficacy rate of 65.3 per cent.
First Non-Chinese Approval

The granting of emergency use approval by Indonesia is a significant development, as it signifies the initial regulatory greenlight for the Sinovac vaccine in a country beyond its country of origin. This action by BPOM precedes any similar approvals by regulatory bodies in other nations outside of China.

Reading history

Hide →

This history is cleared when the page is closed.

What public health strategy will Indonesia adopt with the Sinovac vaccine?

Loading

Was this article helpful?

Helpful

Not helpful

Report an issue

1

0

0

Share with friends